VaxNewMo is developing next generation conjugate vaccines against bacterial diseases using its patented conjugating enzyme technology. Our conjugating enzyme technology is faster, more natural, and more reliable than methods used by pharmaceutical companies.

For more information, visit VaxNewMo or follow their updates on:

Locations

Financials

  • $3m

VaxNewMo Articles

In 2019, BioGenerator Invested $3.2 Million in 16 Bioscience Companies in St. Louis

mm
EQ Staff, Jonathan Allen
3 Min Read

Loading

-
308
Visitors

VaxNewMo’s Vaccine Breakthrough Published in Nature

mm
EQ Staff, Jonathan Allen
2 Min Read

Loading

-
209
Visitors

A “No” from Arch Grants Isn’t a “No” to Your Business

mm
Jonathan Allen
6 Min Read

Loading

-
344
Visitors

Bioscience Startup Founders: Expect Bumps in the Road From Academic to Entrepreneur

mm
Jonathan Allen
4 Min Read

Loading

-
209
Visitors

Meet the Next Generation of Job Creators Winning in St. Louis

mm
Jonathan Allen
4 Min Read

Loading

-
271
Visitors

18 Startups Win $50,000 Each To Locate Their Business In St Louis

mm
Jonathan Allen
4 Min Read

Loading

-
421
Visitors